In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Pfizer's upcoming earnings report, and what the Big Pharma has in store for 2013.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as a bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.
�
No comments:
Post a Comment